A durable installed base, cash generation and improving product cycles can support steady per-share returns. Q1 FY27 revenue grew 13.7% organically and management raised full-year guidance. The key issue is how much acceleration persists after comparisons normalize and whether innovation translates into better group growth and returns on capital. The stock deserves a durable-device valuation, not a speculative technology multiple.

What the Market May Be Mispricing

Debate	Research judgment
Durability of organic growth acceleration	A durable installed base, cash generation and improving product cycles can support steady per-share returns.
Clinical launches, quality and reimbursement	Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.
FCF, dividend coverage and capital allocation	Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00.

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Revenue combines implanted devices, procedure-linked products, capital equipment and recurring consumables. Hospitals, physicians and patients adopt products based on clinical outcomes, training, reimbursement and reliability. Diversification reduces dependence on a single product but also makes group growth slower and harder to change through one successful launch. MiniMed became fully independent on October 15, 2026. Diabetes is therefore excluded from the forward Medtronic business perimeter; the historical statements and September earnings guidance still included it. Cardiovascular, Neuroscience and Surgical are the continuing focus.

Business Takeaway

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.

Aging populations, chronic disease and minimally invasive procedures support demand. Competition is intense in cardiac, surgical and diabetes technologies. Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Boston Scientific (BSX)	Direct segments: cardiac rhythm, EP and neuromodulation	Product scope; no matched operating-scale series	Competes for physician adoption	Customer choice in the stated segment only
Abbott (ABT)	Direct segments: cardiac rhythm, EP and structural heart	Product scope; no matched operating-scale series	Competition must be evaluated by device	Customer choice in the stated segment only
Johnson & Johnson	Direct segments: EP, surgical and selected neuroscience products	Product scope; no matched operating-scale series	Competes in selected procedure categories	Customer choice in the stated segment only

Industry Takeaway

Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Boston Scientific (BSX)	No consistent comparable series	Direct segments: cardiac rhythm, EP and neuromodulation	Focused cardiovascular procedure franchises	Different mix outside overlapping devices	Competes for physician adoption
Abbott (ABT)	No consistent comparable series	Direct segments: cardiac rhythm, EP and structural heart	Established cardiovascular products and clinical relationships	Diagnostics/nutrition do not overlap Medtronic devices	Competition must be evaluated by device
Johnson & Johnson	No consistent comparable series	Direct segments: EP, surgical and selected neuroscience products	Clinical and hospital distribution	Diversified pharmaceuticals are outside the device comparison	Competes in selected procedure categories

Moat Assessment

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. Certain franchises face faster innovators, so the portfolio should be evaluated by product rather than assuming uniform leadership.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2025	33,537	3.62%	65.39%	18.89%	5,185	15.46%	429	1,290	8,965	29,626
FY2026	36,364	8.43%	65.31%	19.98%	5,426	14.92%	457	1,288	9,220	29,149
Q1 FY2027	$9,756	N/D	N/D	18.1%	$1,290 (derived: CFO - capex)	13.2%	$125	1,285.1	$1,691	N/D

Financial Takeaways

Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. TTM FCF of $6.13 billion supports dividends, debt service and reinvestment. The model uses sustainable EPS after ongoing costs, with a lower multiple than faster-growing medtech peers. The October split exchanged the entire 252.8 million-share MiniMed holding for 55.0 million Medtronic shares. Do not add a retained MiniMed investment or dividend to the model. The 2029 EPS assumptions refer to continuing Medtronic after the smaller share base; previously issued full-company FY27 guidance is not a post-separation forecast.

The historical table predates the October MiniMed split. Forward valuation excludes Diabetes and the former MiniMed stake and incorporates cancellation of 55.0 million Medtronic shares. The earnings release’s $5.94–6.00 FY27 EPS guide is historical full-company guidance, not a verified continuing-company update.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$98.88 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$115.84B
Enterprise Value	$135.01B
Trailing P/E	23.31
Provider forward P/E	15.76
EV / Sales	3.60

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
MDT — Medtronic plc	Subject company	Public	15.76	3.60	diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10%
BSX — Boston Scientific Corporation	Direct overlapping cardiovascular/neuro segments	Public	14.14	3.72	medical devices; 3Y revenue-growth estimate 5.49%; operating margin 20.47%
ABT — Abbott	Direct cardiovascular segments; broader group multiple	Public	17.68	4.39	diagnostics, cardiovascular devices and diabetes monitoring; 3Y revenue-growth estimate 9.53%; operating margin 17.68%
Johnson & Johnson	Direct segments: EP, surgical and selected neuroscience products	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes in selected procedure categories

Comparable takeaway: Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 18×, versus the provider's current forward P/E of 15.76×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $78.36, versus the central base FV of $89.50. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 2%; sustainable 2029 EPS $5.00 after compensation; 13× P/E; 11% discount rate; Growth returns to low single digits and 2029 sustainable EPS is $5.	$47.53	25%	Execution, financing or competitive setbacks remain credible	-51.9%
Base	3Y revenue CAGR 6%; sustainable 2029 EPS $6.80 after compensation; 18× P/E; 11% discount rate; Steady product execution produces $6.80 of 2029 sustainable EPS.	$89.50	50%	Most likely operating trajectory, requiring measurable progress	-9.5%
Bull	3Y revenue CAGR 9%; sustainable 2029 EPS $8.50 after compensation; 22× P/E; 11% discount rate; A stronger portfolio cycle produces $8.50 of 2029 sustainable EPS.	$136.73	25%	Successful product conversion and operating leverage; not assured	+38.3%
Probability-Weighted	Sum of each scenario value × its probability	$90.82	100%	Judgmental scenario probabilities	-8.2%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Durability of organic growth acceleration; Clinical launches, quality and reimbursement; FCF, dividend coverage and capital allocation. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $94.63. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Management's improved execution and pipeline progress are encouraging. Portfolio simplification, acquisitions and capital returns should improve per-share economics without starving innovation. Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

Management Takeaway

Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

Analyzed call: Q1 FY2027, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Travis Steed / Bank of America	What supports core growth and margin guidance?	Management said the broad portfolio supports guidance.	Require durable cash conversion after compensation and ongoing investment.
Larry Biegelsen / Wells Fargo	What synergies are expected from the Cornerstone acquisition?	Management said distribution synergies should develop over time.	Judge allocation on per-share returns after financing and dilution.
Vijay Kumar / Evercore	How does the diabetes separation change the business?	Management said the transaction changes the reporting and operating perimeter.	Confirm that this opportunity converts into profitable recurring demand.
Mike Kratky / Leerink	How is Affera adoption supporting the cardiac opportunity?	Management said sequential adoption supports the opportunity.	Confirm that this opportunity converts into profitable recurring demand.
Anthony Petrone / Mizuho	How will capital be allocated after the diabetes separation?	Management said the remaining portfolio must replace the separated growth contribution.	Judge allocation on per-share returns after financing and dilution.
Matt O'Brien / Piper Sandler	What will drive renal-denervation adoption?	Management said clinical evidence and reimbursement drive adoption.	Confirm that this opportunity converts into profitable recurring demand.
Robbie Marcus / JPMorgan	What is the expected margin trajectory for the year?	Management said it is targeting full-year margin improvement.	Require durable cash conversion after compensation and ongoing investment.

Analyst-Q&A Takeaway

Cardiac adoption and margin execution support continuing operations. The now-completed Diabetes separation changes comparability and capital allocation; historical full-company guidance is an inadequate standalone forecast.

Source	Type	Date / Period	What It Supports
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026	Company IR / earnings filing	Q1 FY2027	Latest operating results, guidance, products and financial supplement
MDT complete earnings-call transcript	Transcript	Q1 FY2027	Prepared remarks and all material Q&A exchanges
MDT regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
MDT valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
MDT historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
MDT historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
MDT historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Boston Scientific Corporation statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Abbott statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
MiniMed separation completion	Company IR	2026-10-15	Continuing business perimeter
Final split-off results	Company IR	2026-10-14	55.0 million Medtronic shares exchanged; no retained MiniMed stake
SEC XBRL company facts — MDT	Regulatory filing (as tagged)	FY2027, through 2026-07-31	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Medtronic plc

• Ticker: MDT

• Exchange: NYSE

• Sector / Industry: Health Care / diversified medical devices

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $98.88 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: Yes

• Primary operating period reviewed: Q1 FY2027

• Historical period reviewed: TTM, FY 2026, FY 2025; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q1 FY2027, complete material Q&A

• Latest post-earnings management commentary reviewed: October 15 separation completion and October 14 exchange results

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

MDT — Medtronic plc

Company & Research Metadata

• Company: Medtronic plc

• Ticker: MDT

• Exchange: NYSE

• Sector / Industry: Health Care / diversified medical devices

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $98.88 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: Yes

• Primary operating period reviewed: Q1 FY2027

• Historical period reviewed: TTM, FY 2026, FY 2025; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q1 FY2027, complete material Q&A

• Latest post-earnings management commentary reviewed: October 15 separation completion and October 14 exchange results

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 7 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$98.88 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Hold / Watch
Bear / Base / Bull Fair Value	$47.53 / $89.50 / $136.73
Scenario Probabilities	25% / 50% / 25%
Probability-Weighted Fair Value	$90.82
Probability-Weighted Expected Return	-8.2%
Bear-Case Return	-51.9%
Strong Buy Zone	≤ $52.28
Buy Zone	>$52.28–$72.66
Avoid Chasing Above	> $100.91
Quality Score / Tier	80.4 / Tier A
Opportunity Score / Rank	44.6 / #52 of 76
Risk Level	Medium-High
Tracking / Ownership	Primary Watchlist / Owned

Decision rationale: MDT is Hold / Watch at $94.63, with -4.0% probability-weighted upside and -49.8% bear-case return. A durable installed base, cash generation and improving product cycles can support steady per-share returns. Confidence is 58/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

A durable installed base, cash generation and improving product cycles can support steady per-share returns. Q1 FY27 revenue grew 13.7% organically and management raised full-year guidance. The key issue is how much acceleration persists after comparisons normalize and whether innovation translates into better group growth and returns on capital. The stock deserves a durable-device valuation, not a speculative technology multiple.

What the Market May Be Mispricing

Debate	Research judgment
Durability of organic growth acceleration	A durable installed base, cash generation and improving product cycles can support steady per-share returns.
Clinical launches, quality and reimbursement	Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.
FCF, dividend coverage and capital allocation	Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00.

Business Overview

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Revenue combines implanted devices, procedure-linked products, capital equipment and recurring consumables. Hospitals, physicians and patients adopt products based on clinical outcomes, training, reimbursement and reliability. Diversification reduces dependence on a single product but also makes group growth slower and harder to change through one successful launch. MiniMed became fully independent on October 15, 2026. Diabetes is therefore excluded from the forward Medtronic business perimeter; the historical statements and September earnings guidance still included it. Cardiovascular, Neuroscience and Surgical are the continuing focus.

Business Takeaway

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.

Industry, TAM & Market Share

Aging populations, chronic disease and minimally invasive procedures support demand. Competition is intense in cardiac, surgical and diabetes technologies. Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Boston Scientific (BSX)	Direct segments: cardiac rhythm, EP and neuromodulation	Product scope; no matched operating-scale series	Competes for physician adoption	Customer choice in the stated segment only
Abbott (ABT)	Direct segments: cardiac rhythm, EP and structural heart	Product scope; no matched operating-scale series	Competition must be evaluated by device	Customer choice in the stated segment only
Johnson & Johnson	Direct segments: EP, surgical and selected neuroscience products	Product scope; no matched operating-scale series	Competes in selected procedure categories	Customer choice in the stated segment only

Industry Takeaway

Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets. The base case requires evidence of profitable adoption within that market.

Customer Economics

Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics. Physician training and hospital procurement create switching costs. Pricing pressure and manufacturing quality can offset volume growth, making organic revenue and cash margins more informative than adjusted EPS alone.

Customer-Economics Takeaway

The economic test is FCF, dividend coverage and capital allocation. Pricing pressure and manufacturing quality can offset volume growth, making organic revenue and cash margins more informative than adjusted EPS alone.

Competitive Landscape & Moat

Competitive Landscape

Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Boston Scientific (BSX)	No consistent comparable series	Direct segments: cardiac rhythm, EP and neuromodulation	Focused cardiovascular procedure franchises	Different mix outside overlapping devices	Competes for physician adoption
Abbott (ABT)	No consistent comparable series	Direct segments: cardiac rhythm, EP and structural heart	Established cardiovascular products and clinical relationships	Diagnostics/nutrition do not overlap Medtronic devices	Competition must be evaluated by device
Johnson & Johnson	No consistent comparable series	Direct segments: EP, surgical and selected neuroscience products	Clinical and hospital distribution	Diversified pharmaceuticals are outside the device comparison	Competes in selected procedure categories

Moat Assessment

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. Certain franchises face faster innovators, so the portfolio should be evaluated by product rather than assuming uniform leadership.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2025	33,537	3.62%	65.39%	18.89%	5,185	15.46%	429	1,290	8,965	29,626
FY2026	36,364	8.43%	65.31%	19.98%	5,426	14.92%	457	1,288	9,220	29,149
Q1 FY2027	$9,756	N/D	N/D	18.1%	$1,290 (derived: CFO - capex)	13.2%	$125	1,285.1	$1,691	N/D

Financial Takeaways

Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. TTM FCF of $6.13 billion supports dividends, debt service and reinvestment. The model uses sustainable EPS after ongoing costs, with a lower multiple than faster-growing medtech peers. The October split exchanged the entire 252.8 million-share MiniMed holding for 55.0 million Medtronic shares. Do not add a retained MiniMed investment or dividend to the model. The 2029 EPS assumptions refer to continuing Medtronic after the smaller share base; previously issued full-company FY27 guidance is not a post-separation forecast.

The historical table predates the October MiniMed split. Forward valuation excludes Diabetes and the former MiniMed stake and incorporates cancellation of 55.0 million Medtronic shares. The earnings release’s $5.94–6.00 FY27 EPS guide is historical full-company guidance, not a verified continuing-company update.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Management's improved execution and pipeline progress are encouraging. Portfolio simplification, acquisitions and capital returns should improve per-share economics without starving innovation. Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

Management Takeaway

Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$98.88 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$115.84B
Enterprise Value	$135.01B
Trailing P/E	23.31
Provider forward P/E	15.76
EV / Sales	3.60

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
MDT — Medtronic plc	Subject company	Public	15.76	3.60	diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10%
BSX — Boston Scientific Corporation	Direct overlapping cardiovascular/neuro segments	Public	14.14	3.72	medical devices; 3Y revenue-growth estimate 5.49%; operating margin 20.47%
ABT — Abbott	Direct cardiovascular segments; broader group multiple	Public	17.68	4.39	diagnostics, cardiovascular devices and diabetes monitoring; 3Y revenue-growth estimate 9.53%; operating margin 17.68%
Johnson & Johnson	Direct segments: EP, surgical and selected neuroscience products	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes in selected procedure categories

Comparable takeaway: Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 18×, versus the provider's current forward P/E of 15.76×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $78.36, versus the central base FV of $89.50. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 2%; sustainable 2029 EPS $5.00 after compensation; 13× P/E; 11% discount rate; Growth returns to low single digits and 2029 sustainable EPS is $5.	$47.53	25%	Execution, financing or competitive setbacks remain credible	-51.9%
Base	3Y revenue CAGR 6%; sustainable 2029 EPS $6.80 after compensation; 18× P/E; 11% discount rate; Steady product execution produces $6.80 of 2029 sustainable EPS.	$89.50	50%	Most likely operating trajectory, requiring measurable progress	-9.5%
Bull	3Y revenue CAGR 9%; sustainable 2029 EPS $8.50 after compensation; 22× P/E; 11% discount rate; A stronger portfolio cycle produces $8.50 of 2029 sustainable EPS.	$136.73	25%	Successful product conversion and operating leverage; not assured	+38.3%
Probability-Weighted	Sum of each scenario value × its probability	$90.82	100%	Judgmental scenario probabilities	-8.2%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Durability of organic growth acceleration; Clinical launches, quality and reimbursement; FCF, dividend coverage and capital allocation. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $94.63. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Travis Steed / Bank of America	What supports core growth and margin guidance?	Management said the broad portfolio supports guidance.	Require durable cash conversion after compensation and ongoing investment.
Larry Biegelsen / Wells Fargo	What synergies are expected from the Cornerstone acquisition?	Management said distribution synergies should develop over time.	Judge allocation on per-share returns after financing and dilution.
Vijay Kumar / Evercore	How does the diabetes separation change the business?	Management said the transaction changes the reporting and operating perimeter.	Confirm that this opportunity converts into profitable recurring demand.
Mike Kratky / Leerink	How is Affera adoption supporting the cardiac opportunity?	Management said sequential adoption supports the opportunity.	Confirm that this opportunity converts into profitable recurring demand.
Anthony Petrone / Mizuho	How will capital be allocated after the diabetes separation?	Management said the remaining portfolio must replace the separated growth contribution.	Judge allocation on per-share returns after financing and dilution.
Matt O'Brien / Piper Sandler	What will drive renal-denervation adoption?	Management said clinical evidence and reimbursement drive adoption.	Confirm that this opportunity converts into profitable recurring demand.
Robbie Marcus / JPMorgan	What is the expected margin trajectory for the year?	Management said it is targeting full-year margin improvement.	Require durable cash conversion after compensation and ongoing investment.

Analyst-Q&A Takeaway

Cardiac adoption and margin execution support continuing operations. The now-completed Diabetes separation changes comparability and capital allocation; historical full-company guidance is an inadequate standalone forecast.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
Durability of organic growth acceleration	A durable installed base, cash generation and improving product cycles can support steady per-share returns.	Revenue trajectory sustains approximately 6% annual growth on a comparable basis	Growth remains below the 2% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
Clinical launches, quality and reimbursement	Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.	After-cost earnings progress toward the base implied net margin of 19.0%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
FCF, dividend coverage and capital allocation	Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00.	Financing and compensation remain consistent with 1,144.1M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	86	25%	21.5	Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.
Moat and competitive position	85	25%	21.3	Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat.
Growth runway and durability	74	20%	14.8	Aging populations, chronic disease and minimally invasive procedures support demand.
Financial quality and balance sheet	79	15%	11.9	Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00.
Management, governance and capital allocation	73	15%	11.0	Management's improved execution and pipeline progress are encouraging.
Quality Score	80.4	100%	80.4	Weighted score, independent of ownership and current price

• Quality Tier: A
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	80.4	80.4	30%	24.1
Probability-weighted upside	-8.2%	33.7	35%	11.8
Bear-case downside	-51.9%	0.0	20%	0.0
Risk / valuation confidence	58	58.0	15%	8.7
Opportunity Score		44.6	100%	44.6

• Opportunity Rank: #52 of 76
• Zone Status: Hold / Watch

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: Yes
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$94.63	Hold / Watch	Hold / Watch	>$52.28–$72.66	≤ $52.28	> $100.91	$89.50	$90.82	-4.0%	80.4	47.5 / #39	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026	Company IR / earnings filing	Q1 FY2027	Latest operating results, guidance, products and financial supplement
MDT complete earnings-call transcript	Transcript	Q1 FY2027	Prepared remarks and all material Q&A exchanges
MDT regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
MDT valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
MDT historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
MDT historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
MDT historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Boston Scientific Corporation statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Abbott statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
MiniMed separation completion	Company IR	2026-10-15	Continuing business perimeter
Final split-off results	Company IR	2026-10-14	55.0 million Medtronic shares exchanged; no retained MiniMed stake
SEC XBRL company facts — MDT	Regulatory filing (as tagged)	FY2027, through 2026-07-31	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics